Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasquinimod maintenance after first-line docetaxel in metastatic castration-resistant prostate cancer
2012-001038-32Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Tasquinimod maintenance with Placebo maintenance (2 arms). Primary endpoint: Radiological progression-free survival including skeletal-related events. Started Jul 2012; status: terminated.
02
Drugs
tasquinimod
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2012-001038-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001038-32.